Jin Wen-Yuan, Lin Sheng-Liang, Hou Ruo-Lin, Chen Xiao-Yang, Han Ting, Jin Yan, Tang Li, Zhu Zhi-Wei, Zhao Zheng-Yan
Department of Children's Health Care, Children's Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China.
Department of Epidemiology and Biostatistics, School of Public Health, Curtin University, Perth, WA6845, Australia.
BMC Pregnancy Childbirth. 2016 Mar 21;16:60. doi: 10.1186/s12884-016-0852-9.
Dyslipidemia in pregnancy are associated with gestational diabetes mellitus (GDM), preeclampsia, preterm birth and other adverse outcomes, which has been extensively studied in western countries. However, similar studies have rarely been conducted in Asian countries. Our study was aimed at investigating the associations between maternal dyslipidemia and adverse pregnancy outcomes among Chinese population.
Data were derived from 934 pairs of non-diabetic mothers and neonates between 2010 and 2011. Serum blood samples were assayed for fasting total cholesterol (TC), triglycerides (TG), high-density lipoprotein-cholesterol (HDL-C), and low-density lipoprotein-cholesterol (LDL-C) concentrations during the first, second and third trimesters. The present study explored the associations between maternal lipid profile and pregnancy complications and perinatal outcomes. The pregnancy complications included GDM, preeclampsia and intrahepatic cholestasis of pregnancy (ICP); the perinatal outcomes included preterm birth, small/large for gestational age (SGA/LGA) infants and macrosomia. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated and adjusted via stepwise logistic regression analysis. Optimal cut-off points were determined by ROC curve analysis.
After adjustments for confounders, every unit elevation in third-trimester TG concentration was associated with increased risk for GDM (OR = 1.37, 95% CI: 1.18-1.58), preeclampsia (OR = 1.50, 95% CI: 1.16-1.93), ICP (OR = 1.28, 95% CI: 1.09-1.51), LGA (OR = 1.13, 95% CI: 1.02-1.26), macrosomia (OR = 1.19, 95% CI: 1.02-1.39) and decreased risk for SGA (OR = 0.63, 95% CI: 0.40-0.99); every unit increase in HDL-C concentration was associated with decreased risk for GDM and macrosomia, especially during the second trimester (GDM: OR = 0.10, 95% CI: 0.03-0.31; macrosomia: OR = 0.25, 95% CI: 0.09-0.73). The optimal cut-off points for third-trimester TG predicting GDM, preeclampsia, ICP, LGA and SGA were separately ≥ 3.871, 3.528, 3.177, 3.534 and ≤ 2.530 mmol/L. The optimal cut-off points for third-trimester HDL-C identifying GDM, macrosomia and SGA were respectively ≤ 1.712, 1.817 and ≥ 2.238 mmol/L.
Among Chinese population, maternal high TG in late pregnancy was independently associated with increased risk of GDM, preeclampsia, ICP, LGA, macrosomia and decreased risk of SGA. Relative low maternal HDL-C during pregnancy was significantly associated with increased risk of GDM and macrosomia; whereas relative high HDL-C was a protective factor for both of them.
孕期血脂异常与妊娠期糖尿病(GDM)、子痫前期、早产及其他不良结局相关,西方国家已对此进行了广泛研究。然而,亚洲国家很少开展类似研究。我们的研究旨在调查中国人群中孕妇血脂异常与不良妊娠结局之间的关联。
数据来源于2010年至2011年间的934对非糖尿病母亲及其新生儿。在孕早期、孕中期和孕晚期采集血清血样,检测空腹总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)和低密度脂蛋白胆固醇(LDL-C)浓度。本研究探讨了孕妇血脂水平与妊娠并发症及围产期结局之间的关联。妊娠并发症包括GDM、子痫前期和妊娠肝内胆汁淤积症(ICP);围产期结局包括早产、小于/大于胎龄(SGA/LGA)儿及巨大儿。计算比值比(OR)和95%置信区间(95%CI),并通过逐步逻辑回归分析进行调整。通过ROC曲线分析确定最佳截断点。
在对混杂因素进行调整后,孕晚期TG浓度每升高一个单位,与GDM(OR = 1.37,95%CI:1.18 - 1.58)、子痫前期(OR = 1.50,95%CI:1.16 - 1.93)、ICP(OR = 1.28,95%CI:1.09 - 1.51)、LGA(OR = 1.13,95%CI:1.02 - 1.26)、巨大儿(OR = 1.19,95%CI:1.02 - 1.39)的风险增加以及SGA风险降低(OR = 0.63,95%CI:0.40 - 0.99)相关;HDL-C浓度每升高一个单位,与GDM和巨大儿风险降低相关,尤其是在孕中期(GDM:OR = 0.10,95%CI:0.03 - 0.31;巨大儿:OR = 0.25,95%CI:0.09 - 0.73)。孕晚期TG预测GDM、子痫前期、ICP、LGA和SGA的最佳截断点分别为≥3.871、3.528、3.177、3.534和≤2.530 mmol/L。孕晚期HDL-C识别GDM、巨大儿和SGA的最佳截断点分别为≤1.712、1.817和≥2.238 mmol/L。
在中国人群中,孕晚期孕妇高TG水平与GDM、子痫前期、ICP、LGA、巨大儿风险增加及SGA风险降低独立相关。孕期孕妇相对较低的HDL-C水平与GDM和巨大儿风险显著增加相关;而相对较高的HDL-C水平对二者均为保护因素。